Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls

Detalhes bibliográficos
Autor(a) principal: Galvão, Ana C. de Menezes
Data de Publicação: 2018
Outros Autores: Almeida, Raíssa N. de, Silva, Erick A. dos Santos, Freire, Fúlvio A. M., Palhano-Fontes, Fernanda, Onias, Heloisa, Arcoverde, Emerson, Maia-de-Oliveira, João P., Araújo, Dráulio Barros de, Lobão-Soares, Bruno, Galvão-Coelho, Nicole L.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/jspui/handle/123456789/25440
Resumo: Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary cortisol response were measured at baseline (before dosing session) and 48 h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients, with respect to healthy controls. Salivary cortisol was also measured during dosing session, and we observed higher increases for both C and MD that ingested ayahuasca than placebo. After 48 h from the dosing session with ayahuasca, patients' awakening salivary cortisol response is similar to the ones detected in controls. No significant changes in plasma cortisol levels were observed 48 h after the sessions. Therefore, these findings point to new evidence on the modulation of salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive volunteers. Considering that cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes, it is assumed to be critically involved to the etiology of depression and its regulation seems to be important for the treatment and remission of major depression, ayahuasca use as antidepressant should be further investigated. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.
id UFRN_4f67726e2d3331098df4a383a9f49b8a
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/25440
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Galvão, Ana C. de MenezesAlmeida, Raíssa N. deSilva, Erick A. dos SantosFreire, Fúlvio A. M.Palhano-Fontes, FernandaOnias, HeloisaArcoverde, EmersonMaia-de-Oliveira, João P.Araújo, Dráulio Barros deLobão-Soares, BrunoGalvão-Coelho, Nicole L.2018-06-18T16:43:59Z2018-06-18T16:43:59Z2018-05-08GALVÃO, A.C.M. et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front. Psychiatry v. 9, n.185, maio/2018. DOI: 10.3389/fpsyt.2018.0018510.3389/fpsyt.2018.00185https://repositorio.ufrn.br/jspui/handle/123456789/25440engayahuascaawakening salivary cortisolplasma cortisoltreatment-resistant depressionhypocortisolemiaCortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controlsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleMajor depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary cortisol response were measured at baseline (before dosing session) and 48 h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients, with respect to healthy controls. Salivary cortisol was also measured during dosing session, and we observed higher increases for both C and MD that ingested ayahuasca than placebo. After 48 h from the dosing session with ayahuasca, patients' awakening salivary cortisol response is similar to the ones detected in controls. No significant changes in plasma cortisol levels were observed 48 h after the sessions. Therefore, these findings point to new evidence on the modulation of salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive volunteers. Considering that cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes, it is assumed to be critically involved to the etiology of depression and its regulation seems to be important for the treatment and remission of major depression, ayahuasca use as antidepressant should be further investigated. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNORIGINALDraulioAraujo_ICe_Cortisol modulation_2018.pdfDraulioAraujo_ICe_Cortisol modulation_2018.pdfDraulioAraujo_ICe_Cortisol modulation_2018application/pdf891956https://repositorio.ufrn.br/bitstream/123456789/25440/1/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdfda807f12083380bca1ce540b495aa487MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25440/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTDraulioAraujo_ICe_Cortisol modulation_2018.pdf.txtDraulioAraujo_ICe_Cortisol modulation_2018.pdf.txtExtracted texttext/plain61029https://repositorio.ufrn.br/bitstream/123456789/25440/3/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdf.txt82149d5a5fb5e094d78d86a42088b993MD53THUMBNAILDraulioAraujo_ICe_Cortisol modulation_2018.pdf.jpgDraulioAraujo_ICe_Cortisol modulation_2018.pdf.jpgIM Thumbnailimage/jpeg11204https://repositorio.ufrn.br/bitstream/123456789/25440/4/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdf.jpg964bbda47eeb9c2053ba4bdb0a52511eMD54123456789/254402021-07-08 15:22:38.357oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-07-08T18:22:38Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
title Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
spellingShingle Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
Galvão, Ana C. de Menezes
ayahuasca
awakening salivary cortisol
plasma cortisol
treatment-resistant depression
hypocortisolemia
title_short Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
title_full Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
title_fullStr Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
title_full_unstemmed Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
title_sort Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls
author Galvão, Ana C. de Menezes
author_facet Galvão, Ana C. de Menezes
Almeida, Raíssa N. de
Silva, Erick A. dos Santos
Freire, Fúlvio A. M.
Palhano-Fontes, Fernanda
Onias, Heloisa
Arcoverde, Emerson
Maia-de-Oliveira, João P.
Araújo, Dráulio Barros de
Lobão-Soares, Bruno
Galvão-Coelho, Nicole L.
author_role author
author2 Almeida, Raíssa N. de
Silva, Erick A. dos Santos
Freire, Fúlvio A. M.
Palhano-Fontes, Fernanda
Onias, Heloisa
Arcoverde, Emerson
Maia-de-Oliveira, João P.
Araújo, Dráulio Barros de
Lobão-Soares, Bruno
Galvão-Coelho, Nicole L.
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Galvão, Ana C. de Menezes
Almeida, Raíssa N. de
Silva, Erick A. dos Santos
Freire, Fúlvio A. M.
Palhano-Fontes, Fernanda
Onias, Heloisa
Arcoverde, Emerson
Maia-de-Oliveira, João P.
Araújo, Dráulio Barros de
Lobão-Soares, Bruno
Galvão-Coelho, Nicole L.
dc.subject.por.fl_str_mv ayahuasca
awakening salivary cortisol
plasma cortisol
treatment-resistant depression
hypocortisolemia
topic ayahuasca
awakening salivary cortisol
plasma cortisol
treatment-resistant depression
hypocortisolemia
description Major depression is a highly prevalent mood disorder, affecting about 350 million people, and around 30% of the patients are resistant to currently available antidepressant medications. Recent evidence from a randomized controlled trial (RCT) supports the rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. The aim of this study was to explore the effect of ayahuasca on plasma cortisol and awakening salivary cortisol response, in the same group of treatment-resistant patients (MD) and in healthy volunteers (C). Subjects received a single dose of ayahuasca or placebo (dosing session), and both plasma and awakening salivary cortisol response were measured at baseline (before dosing session) and 48 h after the dosing session. Baseline assessment (D0) showed blunted awakening salivary cortisol response and hypocortisolemia in patients, with respect to healthy controls. Salivary cortisol was also measured during dosing session, and we observed higher increases for both C and MD that ingested ayahuasca than placebo. After 48 h from the dosing session with ayahuasca, patients' awakening salivary cortisol response is similar to the ones detected in controls. No significant changes in plasma cortisol levels were observed 48 h after the sessions. Therefore, these findings point to new evidence on the modulation of salivary cortisol levels as a result of an ayahuasca session, both in healthy and depressive volunteers. Considering that cortisol acts in regulation of distinct physiological pathways, emotional and cognitive processes, it is assumed to be critically involved to the etiology of depression and its regulation seems to be important for the treatment and remission of major depression, ayahuasca use as antidepressant should be further investigated. Moreover, this study highlights the importance of psychedelics in the treatment of human mental disorders.
publishDate 2018
dc.date.accessioned.fl_str_mv 2018-06-18T16:43:59Z
dc.date.available.fl_str_mv 2018-06-18T16:43:59Z
dc.date.issued.fl_str_mv 2018-05-08
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv GALVÃO, A.C.M. et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front. Psychiatry v. 9, n.185, maio/2018. DOI: 10.3389/fpsyt.2018.00185
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/jspui/handle/123456789/25440
dc.identifier.issn.none.fl_str_mv 10.3389/fpsyt.2018.00185
identifier_str_mv GALVÃO, A.C.M. et al. Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front. Psychiatry v. 9, n.185, maio/2018. DOI: 10.3389/fpsyt.2018.00185
10.3389/fpsyt.2018.00185
url https://repositorio.ufrn.br/jspui/handle/123456789/25440
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/25440/1/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdf
https://repositorio.ufrn.br/bitstream/123456789/25440/2/license.txt
https://repositorio.ufrn.br/bitstream/123456789/25440/3/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/25440/4/DraulioAraujo_ICe_Cortisol%20modulation_2018.pdf.jpg
bitstream.checksum.fl_str_mv da807f12083380bca1ce540b495aa487
8a4605be74aa9ea9d79846c1fba20a33
82149d5a5fb5e094d78d86a42088b993
964bbda47eeb9c2053ba4bdb0a52511e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1802117824195330048